KYMR (Kymera Therapeutics) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYMR Kymera Therapeutics Inc KYMR
46 GF Score
Price $103.26
GF Value $24.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kymera Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

KYMR
46GF Score
Kymera Therapeutics Inc KYMR
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kymera Therapeutics (KYMR) Overvalued in 2026?

Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued. The current stock price of $103.26 is trading 324.9% above its estimated GF Value™ of $24.30. GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.

Key valuation signals for KYMR:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $24.30 vs. price of $103.26 (324.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kymera Therapeutics Business Description

Address 500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
46GF Score

Get the complete analysis for KYMR

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$103.26
Price
$24.30
GF Value